Navigation Links
IDM Pharma Reports Third Quarter 2007 Financial Results
Date:11/8/2007

IRVINE, Calif., Nov. 8 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced its financial results for the quarter and nine months ended September 30, 2007. Financial information presented represents the consolidated results of IDM Pharma and its subsidiary, IDM S.A.

Cash and cash equivalents totaled $33.2 million as of September 30, 2007 compared to $37.3 million on June 30, 2007 and $10.2 million on December 31, 2006. The Company's net cash outflow from operations and investment activities for the quarter and nine months ended September 30, 2007, which excludes cash received from financing activities and the effect of exchange rates, was approximately $5.1 million and $14.3 million, respectively.

"During the third quarter we announced our intention to collect additional survival data from the L-MTP-PE Phase 3 trial and submit an amendment to the NDA in the first quarter of 2008," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "In addition, we announced the appointment of Jeff Sherman as our chief medical officer who brings valuable expertise to the management team as we work through the regulatory approval process for L-MTP-PE in the U.S. and Europe, and as we develop our oncology pipeline."

Quarter Ended September 30, 2007

Total revenues in the third quarter of 2007 were $3.1 million compared to total revenues of $3.0 million for the quarter ended September 30, 2006. Substantially all of the revenues for both periods were derived from the Company's collaboration agreement with sanofi-aventis. The $0.1 million increase in revenues in the 2007 period was due to an increase in development costs related to UVIDEM clinical trials, which are reimbur
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 In its latest blog post, ... believes that having family close by during a stay in ... the process is successful, is highlighting a member of the ... the lives of addicts across the country and around the ... can reduce the blood pressure, heart rate, and stress levels ...
(Date:9/17/2014)... sound like the ideas of a science fiction ... an exciting new approach to imaging local and ... prostate cancer, scientists at Virginia Commonwealth University Massey ... Johns Hopkins Medical Institutions have provided proof-of-principle of ... doctors, ability to see tumors that have metastasized ...
(Date:9/17/2014)... NY (PRWEB) September 17, 2014 In ... acknowledges that “bi-weekly telephonic discovery conferences would be beneficial ... such conferences through mid-December. “At the end of December,” ... assess the need for additional conferences. , “The ... recognizes that there is still much to be discussed ...
(Date:9/17/2014)... Dennis Thompson HealthDay Reporter ... in the womb to household chemicals known as phthalates ... Columbia University researchers reported in a new study. ... developing asthma between age 5 and 11 if their ... two phthalates (pronounced thal-ates), the researchers found. The two ...
(Date:9/17/2014)... The Scripps Research Institute (TSRI) have devised a ... effective against vancomycin-resistant strains of MRSA and other ... to have not one but two distinct mechanisms ... evolve resistance quickly. , "This is the prototype ... in clinical use a generation or maybe even ...
Breaking Medicine News(10 mins):Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3
... tend to outlive males, a circumstance that is usually ... especially when they compete for females. This might also ... higher parasite burden than females. Therefore, high variability of ... be more important for males. Scientists at the Research ...
... tests should not be used to predict Alzheimer,s disease, the ... Although there is a link between the two, ... their sense of smell, and it may not necessarily mean ... "A nonspecific association between poor smell function and Alzheimer,s ...
... THURSDAY, May 10 (HealthDay News) -- A new weight-loss ... and Drug Administration showed promising results in a recent ... a combination of the drugs phentermine and topiramate, experienced ... health problems, the study found. The findings were reported ...
... privately insured colon cancer patients found that managed care presence ... surgery to treat colon cancer lowered costs, a national team ... University School of Public Health and Health Services reported in ... cancer is the second leading cause of cancer death in ...
... from systemic sclerosis, also known as scleroderma, than Caucasians. ... a journal of the American College of Rheumatology (ACR), ... likely to have antibodies that increased frequency and severity ... According to the ACR there are 49,000 ...
... Chronic exposure to cocaine reduces the expression of a ... in vivo research on the molecular basis of cocaine ... which produce greater sensitivity to the rewarding effects of ... for development of a treatment for cocaine addiction. It ...
Cached Medicine News:Health News:Living longer - variability in infection-fighting genes can be a boon for male survival 2Health News:Smell Tests Don't Predict Alzheimer's, Study Finds 2Health News:New Weight-Loss Drug Shows Promise in Trial 2Health News:New Weight-Loss Drug Shows Promise in Trial 3Health News:Economic theory actually works in health care 2Health News:Systemic sclerosis complications more severe in African Americans than Caucasians 2Health News:Chronic cocaine use triggers changes in brain's neuron structure 2
(Date:9/17/2014)... YORK , Sept. 17, 2014  Levi & ... in connection with possible claims of breaches of fiduciary ... To get more information, click here: ... you. If you own common stock in ... please contact Eduard Korsinsky, Esq. either via ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire-iReach/ -- ... white paper discussing improvements in the development ... structures for both normal and diseased tissue ... information, simplifies surgical procedures, lowers surgical costs ... surgical procedures. The clinical ...
(Date:9/17/2014)... , Sept. 17, 2014 Bronstein, Gewirtz & ... purchasers of the securities of PDL BioPharma, Inc. ("PDL ... -News).  Such investors are advised to contact Peretz ... Kimelman at info@bgandg.com or 212-697-6484. ... certain of its executives violated federal securities laws. ...
Breaking Medicine Technology:Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
... The Repeater Plus, a handheld manual ... saving time on long series pipetting. Its ... exceptional support for research tasks, and its ... with repetitive work. The nine Combitips allow ...
eValuator fixed-curve diagnostic electrophysiology catheters offer an effective balance between clinical performance and cost....
The True Non-Compliant Balloon....
Medicine Products: